Clinical trials: Rosacea
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Dermatitis, Atopic, Rosacea
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
The purpose of this study is to evaluate the efficacy and tolerance of a gentle facial cleanser in participants with sensitive skin (eczema/atopic dermatitis, rosacea, acne, cosmetic intolerance syndrome).
- Conditions
- Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
- Trial name
- NCT05094700
- Testing
- Non-marketed Cosmetic Facial Cleanser
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Rosacea
An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea
This 4-arm Phase 2 vehicle-controlled study is designed to assess the safety and efficacy of PDI-320, and the individual components, in adult subjects with rosacea.
- Trial name
- NCT01828177
- Testing
- PDI-320, PDI-320 Monad #1, PDI-320 Monad #2
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- PreCision Dermatology, Inc.
Rosacea
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
- Trial name
- NCT02828241
- Testing
- DFD-04 Ointment
- Where
- 8 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Inflammatory Rosacea
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.
- Trial name
- NCT01016782
- Testing
- 0444
- Volunteers
- 867 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Erythema, Rosacea
Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
This is a study to evaluate inter- and intra-rater reliability of the Clinician Erythema Assessment Scale. There is no treatment (intervention) associated with this study.
- Trial name
- NCT01636765
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Allergan
Papulopustular Rosacea
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an…
- Trial name
- NCT00855595
- Testing
- Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
- Where
- 17 sites in United States
- Volunteers
- 207 people
- Sponsor
- LEO Pharma
Rosacea, Erythema
AGN-199201 for the Treatment of Erythema With Rosacea
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT01735201
- Testing
- AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Allergan
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release…
- Trial name
- NCT03864978
- Testing
- Rifaximin delayed release 400 mg tablet
- Where
- 12 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Alfasigma S.p.A.
Rosacea
Mirvaso in Use Study
This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2.
- Trial name
- NCT02249065
- Testing
- Brimonidine
- Where
- 12 sites in United States
- Volunteers
- 205 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
- Trial name
- NCT01555463
- Testing
- Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
- Where
- 49 sites in United States
- Volunteers
- 961 people
- Sponsor
- LEO Pharma
Rosacea
M89PF in Rosacea Associated With Erythema and Sensitive Skin
Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces…
- Trial name
- NCT05562661
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Acne Rosacea
Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea
The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.
- Trial name
- NCT00041977
- Testing
- doxycycline hyclate 20 mg twice daily
- Where
- 7 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- CollaGenex Pharmaceuticals
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Actinic Keratosis, Acne/Rosacea
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
- Conditions
- Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea
- Trial name
- NCT02759900
- Testing
- Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Skin Center Dermatology Group
Rosacea
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
- Trial name
- NCT05597462
- Testing
- Minocycline hydrochloride capsules
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Journey Medical Corporation
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.